Loading...

Sonoma Pharmaceuticals

Nasdaq:SNOA
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SNOA
Nasdaq
$9M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print Invest
  • Sonoma Pharmaceuticals has significant price volatility in the past 3 months.
SNOA Share Price and Events
Price Volatility
SNOA
Industry
5yr Volatility vs Market

SNOA Value

 Is Sonoma Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sonoma Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $1.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sonoma Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sonoma Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:SNOA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-2.85
NasdaqCM:SNOA Share Price ** NasdaqCM (2018-10-19) in USD $1.5
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 28.43x
United States of America Market PE Ratio Median Figure of 2,940 Publicly-Listed Companies 19.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sonoma Pharmaceuticals.

NasdaqCM:SNOA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SNOA Share Price ÷ EPS (both in USD)

= 1.5 ÷ -2.85

-0.53x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sonoma Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Sonoma Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Sonoma Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqCM:SNOA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.53x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
43%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 0.95x
United States of America Market PEG Ratio Median Figure of 2,060 Publicly-Listed Companies 1.28x

*Line of best fit is calculated by linear regression .

NasdaqCM:SNOA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -0.53x ÷ 43%

-0.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sonoma Pharmaceuticals is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sonoma Pharmaceuticals's assets?
Raw Data
NasdaqCM:SNOA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $1.96
NasdaqCM:SNOA Share Price * NasdaqCM (2018-10-19) in USD $1.5
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 162 Publicly-Listed Pharmaceuticals Companies 3.46x
United States of America Market PB Ratio Median Figure of 4,942 Publicly-Listed Companies 1.93x
NasdaqCM:SNOA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SNOA Share Price ÷ Book Value per Share (both in USD)

= 1.5 ÷ 1.96

0.76x

* Primary Listing of Sonoma Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sonoma Pharmaceuticals is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Sonoma Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Sonoma Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SNOA Future Performance

 How is Sonoma Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
43%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sonoma Pharmaceuticals expected to grow at an attractive rate?
  • Sonoma Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3%.
Growth vs Market Checks
  • Sonoma Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Sonoma Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:SNOA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:SNOA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 43%
NasdaqCM:SNOA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 20.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 21.4%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 16.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:SNOA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:SNOA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-03-31 44 2 1
2022-03-31 37 -3 1
2021-03-31 29 -6 1
2020-03-31 23 -10 2
2019-03-31 19 -12 3
NasdaqCM:SNOA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 17 -11 -14
2018-03-31 17 -12 -14
2017-12-31 17 -12 -12
2017-09-30 16 -11 -9
2017-06-30 14 -10 -9
2017-03-31 13 -8 -9
2016-12-31 11 -7 -9
2016-09-30 10 -8 -14
2016-06-30 8 -9 -16
2016-03-31 9 -9 -15
2015-12-31 11 -10 -13
2015-09-30 12 -8 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sonoma Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Sonoma Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:SNOA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Sonoma Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SNOA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-03-31 0.31 0.31 0.31 1.00
2022-03-31 -0.40 -0.40 -0.40 1.00
2021-03-31 -1.02 -1.02 -1.02 1.00
2020-03-31 -1.50 -1.31 -1.69 2.00
2019-03-31 -1.96 -1.79 -2.10 3.00
NasdaqCM:SNOA Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -2.85
2018-03-31 -3.16
2017-12-31 -2.89
2017-09-30 -2.16
2017-06-30 -2.12
2017-03-31 -2.05
2016-12-31 -2.32
2016-09-30 -3.59
2016-06-30 -4.35
2016-03-31 -4.48
2015-12-31 -4.11
2015-09-30 -5.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sonoma Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sonoma Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sonoma Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SNOA Past Performance

  How has Sonoma Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sonoma Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sonoma Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sonoma Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sonoma Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Sonoma Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sonoma Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SNOA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 17.19 -14.28 20.09 1.54
2018-03-31 16.66 -14.33 19.92 1.58
2017-12-31 17.03 -12.49 18.83 1.45
2017-09-30 15.55 -9.22 18.39 1.59
2017-06-30 14.02 -8.99 17.70 1.60
2017-03-31 12.83 -8.67 17.07 1.58
2016-12-31 11.37 -9.41 16.70 1.67
2016-09-30 10.49 -13.71 16.08 1.67
2016-06-30 8.33 -15.57 15.97 1.70
2016-03-31 9.37 -14.72 15.56 1.81
2015-12-31 10.77 -12.56 14.68 1.74
2015-09-30 11.51 -14.26 13.76 1.62
2015-06-30 14.14 -10.47 13.15 1.56
2015-03-31 13.85 -8.20 12.41 1.53
2014-12-31 12.79 0.76 11.91 1.88
2014-09-30 12.86 6.06 11.55 2.29
2014-06-30 13.69 5.38 11.72 2.82
2014-03-31 13.67 3.74 11.56 2.89
2013-12-31 14.09 -6.17 11.69 2.83
2013-09-30 14.34 -7.47 11.46 2.57
2013-06-30 14.77 -7.59 11.87 2.20
2013-03-31 15.45 -6.49 11.89 2.22
2012-12-31 15.47 -5.82 12.12 2.03
2012-09-30 14.72 -6.45 13.17 2.03
2012-06-30 13.86 -5.77 12.52 2.08
2012-03-31 12.74 -7.33 13.20 1.98
2011-12-31 12.10 -7.26 12.76 2.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sonoma Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sonoma Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sonoma Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sonoma Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sonoma Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SNOA Health

 How is Sonoma Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sonoma Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sonoma Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sonoma Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sonoma Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 29.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sonoma Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqCM:SNOA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 12.63 0.48 7.69
2018-03-31 15.33 0.55 10.07
2017-12-31 14.26 0.37 8.63
2017-09-30 16.16 0.45 9.98
2017-06-30 18.61 0.52 12.64
2017-03-31 21.43 0.41 17.46
2016-12-31 22.86 0.06 18.98
2016-09-30 6.04 0.08 3.25
2016-06-30 7.75 0.07 4.97
2016-03-31 10.14 0.11 7.47
2015-12-31 9.12 0.00 6.11
2015-09-30 10.75 0.00 7.97
2015-06-30 11.14 0.04 8.75
2015-03-31 12.05 0.09 6.14
2014-12-31 7.83 0.01 2.24
2014-09-30 13.37 0.01 3.55
2014-06-30 13.40 0.06 4.99
2014-03-31 12.06 0.15 5.48
2013-12-31 3.40 0.05 3.44
2013-09-30 1.55 1.09 3.19
2013-06-30 2.62 1.35 5.38
2013-03-31 4.08 1.94 7.90
2012-12-31 3.13 1.56 6.60
2012-09-30 -0.50 2.57 8.31
2012-06-30 0.34 2.92 4.40
2012-03-31 -0.87 3.24 3.35
2011-12-31 0.16 3.23 4.96
  • Sonoma Pharmaceuticals's level of debt (3.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (51.8% vs 3.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sonoma Pharmaceuticals has sufficient cash runway for 1.4 years based on current financial obligations.
  • Sonoma Pharmaceuticals has sufficient cash runway for 1.4 years if financial obligations continue to reduce at historical rates of -4.9% each year.
X
Financial health checks
We assess Sonoma Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sonoma Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SNOA Dividends

 What is Sonoma Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sonoma Pharmaceuticals dividends.
If you bought $2,000 of Sonoma Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sonoma Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sonoma Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:SNOA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1972 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:SNOA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-03-31
2022-03-31
2021-03-31
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sonoma Pharmaceuticals has not reported any payouts.
  • Unable to verify if Sonoma Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sonoma Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sonoma Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sonoma Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sonoma Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sonoma Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SNOA Management

 What is the CEO of Sonoma Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jim Schutz, image provided by Google.
Jim Schutz
COMPENSATION $689,003
AGE 55
TENURE AS CEO 5.7 years
CEO Bio

Mr. James Schutz, also known as Jim, has been the Chief Executive Officer and President of Oculus Innovative Sciences, Inc. since February 4, 2013. Mr. Schutz served as Vice President of Corporate Development and General Counsel of Oculus Innovative Sciences, Inc. since August 2003 and its Corporate Secretary since June 2006. Mr. Schutz served as Chief Operating Officer of Oculus Innovative Sciences, Inc. From August 2001 to August 2003, Mr. Schutz served as Corporate Secretary and General Counsel at Jomed Inc., (formerly EndoSonic Corp.) an international medical device company. From 1999 to July 2001, he served as in-house counsel at Urban Media Communications Corporation, an Internet/telecom company based in Palo Alto, California. He has been a Director of Oculus Innovative Sciences, Inc. since May 2004. Mr. Schutz graduated from the University of California, San Diego with an B.A. in economics and obtained his law degree from the University of San Francisco School of Law.

CEO Compensation
  • Jim's compensation has increased whilst company is loss making.
  • Jim's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Sonoma Pharmaceuticals management team in years:

9.5
Average Tenure
55
Average Age
  • The average tenure for the Sonoma Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jim Schutz

TITLE
CEO, President & Director
COMPENSATION
$689K
AGE
55
TENURE
5.7 yrs

Bob Miller

TITLE
CFO & Corporate Secretary
COMPENSATION
$518K
AGE
76
TENURE
14.3 yrs

Marc Umscheid

TITLE
Chief Operating Officer
AGE
49
TENURE
0.4 yrs

Robert Northey

TITLE
Executive Vice President of Research & Development
COMPENSATION
$355K
AGE
61

Bruce Thornton

TITLE
Executive Vice President of International Operations & Sales
COMPENSATION
$417K
AGE
54
TENURE
13.3 yrs

Tom Devine

TITLE
General Manager of Dermatology Unit

- Melissa

TITLE
General Manager of Acute Care and Trade unit
Board of Directors Tenure

Average tenure and age of the Sonoma Pharmaceuticals board of directors in years:

4.6
Average Tenure
64
Average Age
  • The tenure for the Sonoma Pharmaceuticals board of directors is about average.
Board of Directors

Jim Schutz

TITLE
CEO, President & Director
COMPENSATION
$689K
AGE
55
TENURE
14.4 yrs

Jerry McLaughlin

TITLE
Lead Independent Director
COMPENSATION
$297K
AGE
70
TENURE
4.6 yrs

Sharon Surrey-Barbari

TITLE
Independent Director
COMPENSATION
$292K
AGE
64
TENURE
4.6 yrs

Philippe Weigerstorfer

TITLE
Independent Director
AGE
59
TENURE
0.1 yrs

Jay Birnbaum

TITLE
Independent Director
COMPENSATION
$347K
AGE
73
TENURE
11.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
15. Mar 18 Buy Robert Miller Individual 12. Mar 18 13. Mar 18 2,400 $9,755.52
13. Mar 18 Buy Robert Miller Individual 09. Mar 18 12. Mar 18 2,400 $9,516.00
09. Mar 18 Buy James Schutz Individual 08. Mar 18 08. Mar 18 2,473 $9,867.27
04. Dec 17 Buy James Schutz Individual 30. Nov 17 30. Nov 17 345 $1,707.75
30. Nov 17 Buy Robert Miller Individual 29. Nov 17 29. Nov 17 1,790 $8,990.80
29. Nov 17 Buy James Schutz Individual 29. Nov 17 29. Nov 17 400 $2,012.00
27. Nov 17 Buy James Schutz Individual 24. Nov 17 24. Nov 17 254 $1,282.70
24. Nov 17 Buy Robert Miller Individual 21. Nov 17 21. Nov 17 2,000 $10,065.00
X
Management checks
We assess Sonoma Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sonoma Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SNOA News

External News
Loading...
Simply Wall St News

Who Owns Most Of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)?

In this article, I will take a quick look at Sonoma Pharmaceuticals Inc’s (NASDAQ:SNOA) recent ownership structure – an unconventional investing subject, but an important one. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

What Should Investors Know About The Future Of Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA)?

Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA) released its most recent earnings update in March 2018, which … company earnings became less negative compared to the previous year's level … as a result of recent tailwinds

Simply Wall St -

Interested In Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)? Here's How It Performed Recently

When Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) released its most recent earnings update (31 March 2018), I wanted to understand how these figures stacked up against its past performance. … The two benchmarks I used were Sonoma Pharmaceuticals's average earnings over the past couple of years, and its industry performance. … SNOA is loss-making, with the most recent trailing twelve-month earnings of -US$14.33m (from 31 March 2018), which compared to last year has become.

Simply Wall St -

Who Owns Most Of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)?

Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … With 5.78% ownership, SNOA insiders is an important ownership type. … This is a positive sign for potential investors as these firms play an important role in aligning company policy with shareholder returns.Next Steps: SNOA's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Does Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA) -32.83% Earnings Drop Reflect A Longer Term Trend?

The two benchmarks I used were Sonoma Pharmaceuticals's average earnings over the past couple of years, and its industry performance. … NasdaqCM:SNOA Income Statement Apr 24th 18 We can further evaluate Sonoma Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years. … Inspecting growth from a sector-level, the US pharmaceuticals industry has been growing its average earnings by double-digit 11.92% over the past twelve months, and a less exciting 9.86% over the previous five years.

Simply Wall St -

What You Must Know About Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA) Financial Strength

Over the past year, SNOA has ramped up its debt from US$114.00K to US$410.00K – this includes both the current and long-term debt. … NasdaqCM:SNOA Historical Debt Apr 10th 18 Can SNOA service its debt comfortably? … SNOA is not taking on too much debt commitment, which may be constraining for future growth.

Simply Wall St -

Loss-Making Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) Expected To Breakeven

See our latest analysis for Sonoma Pharmaceuticals According to the industry analysts covering SNOA, breakeven is near. … Therefore, SNOA is expected to breakeven roughly 4 years from now. … For a more comprehensive look at SNOA, take a look at SNOA’s company page on Simply Wall St.

Simply Wall St -

Is It Time To Buy Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. … The stock’s ratio of 1.28x is currently trading slightly below its industry peers’ ratio of 2.59x, which means if you buy Sonoma Pharmaceuticals today, you’d be paying a relatively reasonable price for it. … And if you believe Sonoma Pharmaceuticals should be trading in this range, then there isn’t much room for the share price grow beyond what it’s currently trading.

Simply Wall St -

Flavor Of The Month: Sonoma Pharmaceuticals And More

SNOA ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. … USNA ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. … Moreover, the 27.18% growth in operating cash flows shows that a decent part of earnings is driven by robust cash generation from operational activities, not one-off or non-core activities.

Simply Wall St -

What You Must Know About Sonoma Pharmaceuticals Inc's (NASDAQ:SNOA) Financial Strength

How does SNOA’s operating cash flow stack up against its debt? … However, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … This indicates room for improvement as its cash flow covers less than a quarter of its borrowings, which means its operating efficiency could be better.

Simply Wall St -

SNOA Company Info

Map
Description

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. It also provides Mondoxyne, a doxycycline-based prescription oral tetracycline antibiotic used as a treatment for acne vulgaris; Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; and Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.

Details
Name: Sonoma Pharmaceuticals, Inc.
SNOA
Exchange: NasdaqCM
Founded: 1999
$9,395,467
6,479,633
Website: http://www.sonomapharma.com
Address: Sonoma Pharmaceuticals, Inc.
1129 North McDowell Boulevard,
Petaluma,
California, 94954,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SNOA Common Stock Nasdaq Capital Market US USD 25. Jan 2007
DB A2DHV2 Common Stock Deutsche Boerse AG DE EUR 25. Jan 2007
Number of employees
Current staff
Staff numbers
79
Sonoma Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/19 21:18
End of day share price update: 2018/10/19 00:00
Last estimates confirmation: 2018/08/10
Last earnings filing: 2018/08/08
Last earnings reported: 2018/06/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.